A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo

Blood

Volumn 113, Issue 15, 2009, Pages 3397-3405

  Cerchietti, Leandro C ^a   Yang, Shao Ning ^a   Shaknovich, Rita ^b   Hatzi, Katerina ^a   Polo, Jose M ^c   Chadburn, Amy ^b   Dowdy, Steven F ^d   Melnick, Ari ^a,b  

^a Department of Medicine   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BCL6 PEPTIDE INHIBITOR; DEXTRO AMINO ACID; PEPTIDE DERIVATIVE; PROTEIN BCL 6; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SPECIFICITY; GERMINAL CENTER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MALE; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN MOTIF; SINGLE DRUG DOSE; XENOGRAFT;

EID: 65349119454     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-168773     Document Type: Article

References (23)

1. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997; 16:161-170.
2. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997;276:589-592.
3. Ranuncolo SM, Polo JM, Dierov J, et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol. 2007;8:705-714.
4. Phan RT, Dalla-Favera R. The BCL6 proto- oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432:635-639.
5. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol. 2005;6:1054-1060.
6. Shaffer AL, Lin KI, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002;17:51-62.
7. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol. 2004;173:1158-1165.
8. Ye BH, Lista F, Lo Coco F, et al. Alterations of a
9. zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science. 1993;262:747-750.
10. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341-346.
11. Ahmad KF, Melnick A, Lax S, et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell. 2003;12:1551-1564.
12. Polo JM, Dell'OsoT, Ranuncolo SM, et al. Specific peptide interference reveals BCL6 transcrip- tional and oncogenic mechanisms in B-cell lym-phoma cells. Nat Med. 2004;10:1329-1335.
13. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated trans-duction in the treatment of cancer. Adv Drug Deliv Rev. 2005;57:579-596.
14. Wadia JS, Stan RV, DowdySF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocyto-sis. Nat Med. 2004;10:310-315.
15. Polo JM, Juszczynski P, Monti S, et al. Transcrip-tional signature with differential expression of BCL6 target genes accurately identifies BCL6- dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA. 2007;104:3207-3212.
16. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol. 2004;2:E36.
17. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105: 1851-1861.
18. Baron BW, Anastasi J, Montag A, et al. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A. 2004;101:14198-14203.
19. Cattoretti G, Pasqualucci L, Ballon G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lym-phomas in mice. Cancer Cell. 2005;7:445-455.
20. Melnick A, Carlile G, Ahmad KF, et al. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol Cell Biol. 2002;22:1804-1818.
21. Parekh S, Polo JM, Shaknovich R, et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood. 2007;110:2067-2074.
22. Mendez L, Polo J, Yu J, et al. CtBP is an essential corepressor for BCL6 autoregulation. Mol Cell Biol. 2008; 28:2175-2786.
23. Toney LM, Cattoretti G, Graf JA, et al. BCL-6 regulates chemokine gene transcription in macro-phages. Nat Immunol. 2000;1:214-220.